![]() |
|
|
Vol. 31, Issue 3, 282-288, March 2003
BIBRA International Ltd., Carshalton, Surrey (R.J.P, A.B.R, B.G.L.); Section on Clinical Pharmacology, Division of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London (R.J.E., P.S.W., A.R.B.); and Institute of Liver Studies, Guy's, King's and St. Thomas' School of Medicine, London, United Kingdom (J.M.T.)
| |
Abstract |
|---|
|
|
|---|
Precision-cut human liver slices obtained from 11 donors were
cultured for 72 h in a defined medium (serum free Williams' medium E) supplemented with 0.1 µM insulin and 0.1 µM dexamethasone (DEX). Liver slices were treated with 50 µM concentrations of
-naphthoflavone (BNF), lansoprazole, rifampicin (RIF), DEX and methylclofenapate and 500 µM sodium phenobarbital (NaPB). The relative apoprotein levels of 12 cytochrome P450 (P450) enzymes were determined in liver slice microsomes using a panel of antipeptide antibodies. Treatment with BNF significantly induced mean levels of
CYP1A2 apoprotein to 160% of levels in 72-h control (no test compound)
human liver slice microsomes. NaPB significantly induced levels of
CYP3A4 apoprotein to 255% of control and RIF significantly induced
levels of CYP2C19 and CYP3A4 apoproteins to 265 and 330% of control,
respectively. In addition, treatment with RIF increased levels of
CYP2A6 apoprotein to 205% of control, and treatment with both NaPB and
RIF increased levels of CYP2B6 apoprotein to 370 and 615% of control,
respectively. However, these increases were not statistically
significant, owing to a variable response between liver slice
preparations from different subjects, this being apparent for all
inducible P450s. In contrast, none of the compounds examined
significantly increased levels of CYP2C8, CYP2C9, CYP2D6, CYP2E1, and
CYP4A11 apoproteins. Levels of CYP1A1 apoprotein were not detected in
any liver slice sample, either before or after treatment with the model
inducers. Overall, these results demonstrate the utility of cultured
human liver slices for assessing the effects of chemicals on P450 enzymes.
| |
Introduction |
|---|
|
|
|---|
Hepatic
cytochrome P450 (P4501) enzymes are known to have
a major role in the metabolism of both xenobiotics (including
therapeutic agents) and certain endogenous compounds (Nelson et al.,
1996
; Parkinson, 1996
; Pelkonen et al., 1998
). In the development of new therapeutic agents, it is important to ascertain whether the compound will be an inducer or an inhibitor of P450 enzymes, to minimize potential drug interactions (Lin and Lu, 1998
; Pelkonen et
al., 1998
; Tucker et al., 2001
). While P450 inhibition studies are
normally performed with either human liver microsomes or cDNA-expressed P450 enzymes, cultured human hepatocytes have been extensively used for
P450 induction studies (Maurel, 1996
; Li et al., 1997
; Tucker et al.,
2001
). P450 induction in cultured hepatocytes may be assessed by a
variety of techniques including measurement of mRNA levels, apoprotein
levels and monooxygenase activities. By employing such techniques, the
induction of P450 enzymes in the CYP1A, CYP2A, CYP2B, CYP2C, CYP2E, and
CYP3A subfamilies in cultured human hepatocytes has been reported by a
number of laboratories (Curi-Pedrosa et al., 1994
; Donato et al., 1995
;
Chang et al., 1997
; Kostrubsky et al., 1999
; Meunier et al., 2000
;
Rodríguez-Antona et al., 2000
; Sahi et al., 2000
;
Gerbal-Chaloin et al., 2001
).
A number of studies have demonstrated that precision-cut liver slices
may be an alternative in vitro liver model system to isolated
hepatocytes. Liver slices maintain tissue architecture, so that all
cell types are present, and like hepatocytes have been extensively used
for studies of xenobiotic metabolism and xenobiotic-induced toxicity
(Bach et al., 1996
; Lerche-Langrand and Toutain, 2000
). In contrast to
cultured human hepatocytes, relatively few investigations have examined
the use of human liver slices for P450 enzyme induction studies. The
majority of these studies have focused on the induction of CYP1A
enzymes, as determined by effects on marker enzyme activities,
apoprotein levels, and/or mRNA levels. For example, Aroclor 1254,
-naphthoflavone (BNF), 3,3'-diindolylmethane, omeprazole, and
2,3,7,8-tetrachlorodibenzo-p-dioxin have been reported to
induce CYP1A enzymes in cultured human liver slices (Lake et al., 1996
,
1998
; Olson et al., 1997
; Drahushuk et al., 1998
; Glöckner et
al., 1999
). In one study rifampicin (RIF) was reported to induce CYP3A4
(Lake et al., 1997
), and in a recently published abstract,
cyclophosphamide and phenobarbital were reported to induce CYP2B6 and
CYP3A4 in cultured human liver slices (Martin et al., 2002
).
The aim of this study was to examine the inducibility of the major
hepatic P450 enzymes, namely members of the CYP1A, CYP2B, CYP2C, CYP2D,
CYP2E, CYP3A, and CYP4A subfamilies, in cultured human liver slices.
Unlike previous studies (Lake et al., 1996
, 1997
, 1998
; Drahushuk et
al., 1998
; Glöckner et al., 1999
), where relatively small numbers
(up to six preparations) of human liver slices were evaluated, in the
present study liver slice preparations from 11 donors were examined.
The model inducers selected comprised BNF, dexamethasone (DEX),
lansoprazole (LANS), RIF, and sodium phenobarbital (NaPB), which are
all known to induce various P450 enzymes in human hepatocytes
(Curi-Pedrosa et al., 1994
; Donato et al., 1995
; Maurel, 1996
; Chang et
al., 1997
; Pelkonen et al., 1998
; Meunier et al., 2000
; Gerbal-Chaloin
et al., 2001
). Human liver slices were also treated with
methylclofenapate (MCP), which is a potent rodent peroxisome
proliferator and CYP4A enzyme inducer (Lake, 1995
). In keeping with
their known in vivo properties, MCP and other rodent peroxisome
proliferators have been shown to produce peroxisome proliferation,
induction of peroxisomal fatty acid oxidizing enzyme and levels of
CYP4A apoproteins in cultured rat liver slices (Beamand et al., 1993
;
Lake et al., 1996
).
Precision-cut liver slices were treated with the test compounds for
72 h, as this treatment period has been previously shown to be
suitable to observe induction of P450 enzyme activities and apoprotein
levels in cultured human liver slices (Lake et al., 1996
, 1997
, 1998
).
Levels of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, CYP3A4,
CYP3A5, and CYP4A11 apoproteins were quantified by immunoblotting with
a panel of fully characterized monospecific antipeptide antibodies
(Edwards et al., 1998
). In addition, levels of CYP2C enzymes were
quantified with an antibody that binds to CYP2C8, CYP2C9, and CYP2C19,
these P450 forms being readily separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (Edwards et al., 1998
).
Finally, limited studies were also performed with some enzymatic
markers, namely 7-ethoxyresorufin O-deethylase, 7-ethoxy-4-trifluormethylcoumarin O-deethylase, and
testosterone 6
-hydroxylase.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
The sources of the tissue culture materials were as described
previously (Beamand et al., 1993
). BNF, DEX, LANS, NaPB, RIF,
-naphthoflavone, 7-ethoxyresorufin, testosterone, resorufin, 6
-hydroxytestosterone, enzyme cofactors, prestained molecular weight
markers, and protein G coupled to horseradish peroxidase were purchased
from Sigma-Aldrich Co. Ltd. (Poole, Dorset, UK). MCP was purchased from
Lancaster Synthesis (Morecambe, Lancs, UK) and
7-ethoxy-4-trifluoromethylcoumarin and
7-hydroxy-4-trifluoromethylcoumarin from Enzyme System Products
(Livermore, CA). [4-14C]Testosterone (specific
activity 56 mCi/mmol) was obtained from Amersham Pharmacia Biotech UK
Ltd. (Little Chalfont, Buckinghamshire, UK) and SDS-polyacrylamide gel
electrophoresis reagents from National Diagnostics (Aylesbury, Bucks, UK).
Preparation of Liver Slices. Samples of human liver were collected and transported to BIBRA on ice (BIBRA International Ltd., Carshalton, Surrey, UK. The donors of the 11 human liver samples, designated subjects A to K, were female subjects aged 31, 38, 55, and 11 years, male subjects aged 13, 50, 10, 24, 25, and 66 years, and a female subject aged 17 years, respectively. The Research Ethics Committee of King's College Hospital and the donor's representatives had granted approval for the use of this tissue, which was surplus to clinical requirements. Tissue cylinders from liver samples were prepared using a 10-mm diameter motor-driven tissue-coring tool. From the cylinders, tissue slices (200-300 µm) were prepared in cold oxygenated (95% O2/5% CO2) Earle's balanced salt solution containing 25 mM D-glucose, 50 µg/ml gentamicin, and 2.5 µg/ml fungizone using a Krumdieck tissue slicer (Alabama Research and Development Corp., Munford, AL).
Culture of Liver Slices. Liver slices were floated onto Vitron Inc. (Tucson, AZ) type C titanium roller inserts (two slices per insert) and cultured at 2 rpm in glass vials containing 1.7 ml of culture medium employing a Vitron dynamic organ culture incubator, which was operated in accordance with the manufacturers' instructions. The culture medium consisted of serum free Williams' medium E containing 2 mM L-glutamine, 0.1 µM insulin, 0.1 µM DEX, 50 µg/ml gentamicin, and 2.5 µg/ml fungizone. Liver slice cultures were maintained at 37°C in an atmosphere of 95% O2/5% CO2. After 1 h, treatment was commenced by replacing the culture medium with fresh medium containing the required concentrations of the test compounds. BNF, DEX, LANS, MCP, and RIF were dissolved in dimethyl sulfoxide (DMSO) prior to addition to the culture medium, whereas NaPB was dissolved directly in the culture medium. The final DMSO concentration was 0.4% (v/v) in all vials including the control cultures. Subsequently, the medium was replaced every 24 h and the slices redosed with fresh medium containing the test compounds. Following each medium change and returning the vials to the incubator, the gas flow was increased for 10 s to restore the high oxygen atmosphere.
Biochemical Investigations with Liver Slices.
Freshly cut and 72-h cultured liver slices were washed in ice-cold
0.154 M KCl containing 50 mM Tris-HCl, pH 7.4, homogenized in this
medium by sonication (Beamand et al., 1993
), and stored at
80°C.
Liver slice homogenates (prepared from 16-20 slices) were centrifuged
at 10,000g average for 15 min to obtain the
postmitochondrial supernatant fraction and subsequently at
158,000g average for 40 min to separate the microsomal
fraction from the cytosol. Microsomal fractions were resuspended in
0.154 M KCl containing 50 mM Tris-HCl, pH 7.4, and 2 mM EDTA and
aliquots stored at
80°C. Protein was determined as described
previously (Renwick et al., 2000
). In some experiments liver slice
unwashed microsomal fractions were assayed for activities of
7-ethoxyresorufin O-deethylase and testosterone 6
-hydroxylase as described previously (Renwick et al., 2000
). The
activity of 7-ethoxy-4-trifluoromethylcoumarin O-deethylase was determined directly at 37°C in spectrofluorimeter cuvettes containing 5 µM substrate (added in 5 µl DMSO), 5 µM
-naphthoflavone (added in 5 µl DMSO), 1 mM
NADP+, 7.5 mM DL-isocitric
acid, 1 unit/ml isocitric dehydrogenase, 5 mM
MgSO4, 0.15 to 0.20 mg microsomal protein and 100 mM phosphate buffer, pH 7.4, in a final volume of 2 ml.
7-Hydroxy-4-trifluoromethylcoumarin formation was monitored at
wavelengths of 410 nm excitation and 510 nm emission.
-Naphthoflavone was added to inhibit the contribution of CYP1A2 to
this reaction (Code et al., 1997
).
Immunoblotting.
Immunoblotting was performed using 10 to 100 µg of liver slice
unwashed microsomal protein, as appropriate, as described previously (Renwick et al., 2000
). The levels of CYP1A2, CYP2A6, CYP2B6, CYP2C8,
CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, and CYP4A11 were determined as
amounts relative to those present in a pooled microsomal preparation of
six normal human livers. The relative levels of CYP2C19 were assessed
by using a single sample of human liver microsomes that contained a
readily detectable amount of CYP2C19. For CYP1A1, a sample of
microsomes from baculovirus-infected insect cells containing
cDNA-expressed CYP1A1 (BD Gentest, Woburn, MA; obtained from Cambridge
Bioscience, Cambridge, UK) was used as reference. Immunoreactive band
intensity was quantified using a Kodak Image Station and Kodak Digital
Science ID Image analysis software (PerkinElmer Life Sciences,
Hounslow, UK).
Statistical Analysis. The data were analyzed using Student's paired t test.
| |
Results |
|---|
|
|
|---|
Effect of Model Inducers on Levels of P450 Apoproteins. Immunoblotting of freshly cut and 72-h cultured human liver slice microsomes was performed to assess the relative levels of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, and CYP4A11 apoproteins. Because of the small amounts of material available, it was not possible to examine the effects of all of the inducers studied on liver slices from every donor. However, the effects of each of the model inducers were determined on levels of all the P450 apoproteins evaluated in this study.
As reported previously (Renwick et al., 2000
|
|
|
|
Variability in Induction of P450 Apoproteins in Human Liver Slices.
For all the inducible P450 enzymes, variability was observed among
individual donors in the magnitude of the response to the model
inducers. This variability is illustrated in Figs.
5 and 6 for
the effect of NaPB and RIF on levels of CYP3A4 and CYP2B6 apoproteins.
Figure 5 shows the effect of NaPB and RIF on levels of CYP3A4
apoprotein in 72-h cultured liver slices from each individual subject.
The effect of NaPB was studied in liver slices from all eleven
subjects, whereas the effect of RIF was evaluated in liver slices from
all but one subject (subject C). Whereas little response to the two
model inducers was observed in liver slice preparations from some
subjects (e.g., subjects A and E), a marked response to both NaPB and
RIF was observed with liver slices from other subjects (e.g., subjects
G, H, and J). Overall, CYP3A4 apoprotein levels following treatment
with NaPB and RIF in these studies ranged from 125 to 450 and from 100 to 1840% of control, respectively (Fig. 5). The effect of NaPB and RIF
was evaluated with five subjects where the liver slice preparations
contained detectable levels of CYP2B6 apoprotein (Fig. 6). Compared
with levels of CYP2B6 apoprotein in 72-h cultured control liver slice
microsomes, both model inducers produced
2-fold increases in CYP2B
apoprotein levels. For these human liver slice preparations, following
treatment with NaPB and RIF CYP2B6 apoprotein levels ranged from 200 to 1740 and from 310 to 1395% of control, respectively (Fig. 6).
|
|
Effect of Model Inducers on Levels of CYP1A2, CYP2B6, and CYP3A4
Enzyme Activities and Apoproteins.
In some experiments there was sufficient material available from a
donor sample to determine enzymatic markers for CYP1A2, CYP2B6, and
CYP3A4 in microsomes from liver slices cultured for 72 h with BNF,
LANS, NaPB, RIF, DEX, and MCP. The activities of 7-ethoxyresorufin
O-deethylase, 7-ethoxy-4-trifluoromethylcoumarin O-deethylase and testosterone 6
-hydroxylase (all
expressed as percentage of 72-h control human liver slice microsome
levels) were then compared with levels of their respective P450
apoproteins (normalized to their respective 72-h control values). Good
correlations were observed between 7-ethoxyresorufin O
deethylase activity and CYP1A2 apoprotein levels
(r2 = 0.858; Fig.
7A) and between testosterone
6
-hydroxylase activity and CYP3A4 apoprotein levels
(r2 = 0.643; Fig. 7C).
|
-naphthoflavone to inhibit CYP1A2 activity,
this substrate is not specific for CYP2B6, being also metabolized by
other P450 enzymes in human liver (Bogaards et al., 1996| |
Discussion |
|---|
|
|
|---|
The aim of the current study was to examine the usefulness of
cultured precision-cut human liver slices as an in vitro liver model
system for P450 induction studies. By employing a characterized panel
of highly specific antipeptide antibodies (Edwards et al., 1998
), the
effect of a range of model inducers on the levels of twelve P450
apoproteins in 72-h culture human liver slices was determined. At the
concentrations examined, BNF, NaPB, and RIF all significantly increased
levels of one or more P450 apoproteins in cultured human liver slices.
Whereas the majority of this work was conducted by measuring apoprotein
levels, some limited studies were also performed with enzymatic
markers. Good correlations were obtained between levels of CYP1A2 and
CYP3A4 apoproteins and their respective enzymatic markers, suggesting
that the increased levels of apoproteins observed after treatment with
the model inducers were catalytically active.
The treatment of human liver slices with BNF resulted in an increase in
CYP1A2 apoprotein levels, presumably via an aryl-hydrocarbon receptor-dependent mechanism. This is consistent with the results of
studies on the effects of BNF on CYP1A2 in cultured human hepatocytes by some workers (Curi-Pedrosa et al., 1994
; Meunier et al., 2000
; Sahi
et al., 2000
) but not by others (Liu et al., 2001
). In the present
study, CYP1A1 apoprotein levels remained below the limit of detection,
even after treatment with BNF and LANS. This contrasts with results of
some previous studies with human hepatocytes (Curi-Pedrosa et al.,
1994
; Allen et al., 2001
; Liu et al., 2001
) and liver slices (Drahushuk
et al., 1998
). However, the differential induction of CYP1A apoproteins
in the present study is entirely consistent with the response of such
inducers in vivo (Sesardic et al., 1990
). The absence of detectable
levels of CYP1A1 apoprotein is in agreement with other studies using
this panel of antipeptide antibodies performed both in cultured human
liver slices (Renwick et al., 2000
) and freshly isolated liver
microsomes (Edwards et al., 1998
). There is evidence that hepatic
CYP1A1 in humans is subject to negative regulation (Piechocki and
Hines, 1998
), whereas CYP1A2 is constitutively expressed and inducible
in adult liver (Pelkonen et al., 1998
).
Previous studies have demonstrated that NaPB and RIF can induce a
number of P450 enzymes in human hepatocytes (Curi-Pedrosa et al., 1994
;
Chang et al., 1997
; Meunier et al., 2000
; Rodríguez-Antona et
al., 2000
; Sahi et al., 2000
; Gerbal-Chaloin et al., 2001
). In the
present study, NaPB significantly increased levels of CYP3A4 apoprotein, and RIF significantly increased levels of CYP2C19 and
CYP3A4 apoproteins. Treatment with RIF appeared to increase levels of
CYP2A6 apoprotein in some subjects and treatment with both NaPB and RIF
increased levels of CYP2B6 apoprotein in all subjects where
constitutive levels of CYP2B6 were detectable. However, these increases
were not statistically significant, although the type II error was
quite large due to the limited number of human liver slice preparations
that expressed these P450 apoproteins at detectable levels and the
variability in response between individual subjects. The effects of
NaPB and RIF on CYP2B6 and CYP3A4 were qualitatively similar to those
observed in a previous study where mRNA levels were quantified in
cultured human hepatocytes (Goodwin et al., 2001
). Additional studies
are required to fully evaluate the effects of NaPB and RIF on levels of
CYP2A6 and CYP2B6 apoproteins in cultured human liver slices.
In terms of the overall mean values for all the P450s examined, both
NaPB and RIF produced the largest increases in levels of CYP2B6
apoprotein. These results with cultured liver slices support previous
studies with hepatocytes (Chang et al., 1997
; Rodríguez-Antona
et al., 2000
; Sahi et al., 2000
; Gerbal-Chaloin et al., 2001
), that
this P450 enzyme is markedly inducible in human liver. Although both
NaPB and RIF significantly increased levels of CYP3A4 apoprotein,
neither compound produced a significant increase in levels of CYP3A5
apoprotein, suggesting that this P450 enzyme is less responsive than
CYP3A4 to model inducers. Similar observations have been reported in
cultured human hepatocytes (Rae et al., 2001
).
The effects of DEX on P450 expression in human hepatocytes are complex,
due in part to the physiological role of glucocorticoids in maintaining
expression of the pregnane X receptor and the constitutive androstane
receptor (Pascussi et al., 2001
). In the present studies, the fully
defined culture medium was supplemented with 0.1 µM insulin and 0.1 µM DEX. At these levels it has been reported that DEX can enhance the
induction of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 mRNA levels in human
hepatocytes by NaPB and RIF (Pascussi et al., 2001
). At the 50 µM
concentration examined in the present study, DEX had no significant
effect on levels of P450 apoproteins in cultured human liver slices.
However, in human hepatocytes, DEX has been shown to induce several
P450 enzymes including CYP2A6, CYP2B6, CYP2C8, CYP2C9, and CYP3A4
(Donato et al., 1995
; Chang et al., 1997
; Meunier et al., 2000
; Sahi et
al., 2000
; Gerbal-Chaloin et al., 2001
). In these studies, the effects
of DEX were examined over a wide range of concentrations from
submicromolar up to 500 µM. Additional studies are required to
evaluate the effects of a wide range of concentrations of DEX,
including omitting DEX from the standard medium, on P450 enzymes in
cultured human liver slices.
In recent years much progress has been made in elucidating the various
pathways and receptors involved in the regulation of P450 enzymes in
mammalian liver (Waxman, 1999
; Honkakoski and Negishi, 2000
;
Gerbal-Chaloin et al., 2001
). From the results obtained in this study,
as with cultured hepatocytes, the various pathways for induction of
CYP1A, CYP2A, CYP2B, CYP2C, and CYP3A subfamily P450 enzymes are
retained in cultured human liver slices. In contrast to these P450
enzymes, none of the model inducers examined increased levels of
CYP2D6, CYP2E1, and CYP4A11 apoproteins in 72-h cultured human liver
slices. For CYP2D6, previous studies have suggested that this P450
enzyme is refractory to induction by known inducers of other P450
subfamilies (Parkinson, 1996
; Rodríguez-Antona et al., 2000
).
Treatment with the rodent peroxisome proliferator MCP resulted in a
reduction in the levels of liver slice CYP4A11 apoprotein. MCP had a
similar effect on CYP2C9 apoprotein but had little effect on the other
P450s examined. The effects of MCP thus appear to be selective and not
due to a reduction in the functional viability of the human liver slice
preparations. These results provide further evidence for species
differences in the hepatic effects of rodent peroxisome proliferators
(Lake, 1995
).
For all of the inducible P450 enzymes examined in this study, marked
variability in both the expression levels and the magnitude of
induction was observed between liver slices from different donors. This
variability is illustrated in Figs. 5 and 6 for the effect of NaPB and
RIF on levels of CYP3A4 and CYP2B6 apoproteins. Despite this
variability, both compounds increased CYP3A4 apoprotein levels in the
majority of the subjects examined, with CYP2B6 apoprotein being
increased in all samples where it could be detected. Variability in
response to model inducers has also been observed in previous studies
with cultured human hepatocytes (Curi-Pedrosa et al., 1994
; Maurel,
1996
; Meunier et al., 2000
; Gerbal-Chaloin et al., 2001
) and liver
slices (Lake et al., 1997
, 1998
). Recently, Martin et al. (2002)
suggested that the variability between subjects in CYP2B6 and CYP3A4
induction was less in human liver slices than in hepatocytes.
Such variability in response between subjects may be due to a number of
factors. Due to genetic and environmental factors, the expression of
CYP3A (Koch et al., 2002
) and other P450 genes can vary considerably
between subjects. In addition, for some of the P450s studied,
polymorphisms are known to exist, and these will account for some of
the nondetectable levels. Possibly, polymorphisms may also result in a
reduced stability of P450 apoproteins. Another important factor is
tissue quality. The extent to which this affects the induction response
is not known, but it may be worthwhile including appropriate viability
markers in liver slice P450 induction studies. For example, some
workers have used a slice potassium content of 40 µmol/g or greater
to assess the suitability of human liver slice preparations for CYP1A
induction studies (Olson et al., 1997
; Drahushuk et al., 1998
).
Overall, the available data suggests that it is desirable to examine a
number of human hepatocyte or liver slice preparations to assess the
effects of a new chemical entity on P450 enzymes. It is important to
assess baseline specific apoprotein content, to avoid poor metabolizesr
("null") samples. Moreover, as recommended for P450 induction
studies with human hepatocytes (Li et al., 1997
; Tucker et al., 2001
),
suitable positive controls (e.g., BNF, NaPB, RIF) need to be included
in P450 induction studies employing human liver slices, and replicate
experiments should be performed. When assessing the effects of new
compounds it may also be worthwhile to evaluate potential toxicity to
the liver slices, by including appropriate viability markers in the
experimental design.
In conclusion, these results demonstrate the utility of cultured human liver slices for assessing the effects of chemicals on P450 enzymes.
| |
Footnotes |
|---|
Received August 26, 2002; accepted November 26, 2002.
We gratefully acknowledge the provision of financial support by a grant from the Commission of the European Communities (Project "Eurocyp", BIOMED Contract No. BMH4-CT96-0254) and a Realizing Our Potential Award from the Medical Research Council.
Address correspondence to: Professor Brian G. Lake BIBRA International Ltd. Woodmansterne Road, Carshalton, Surrey SM5 4DS UK. E-mail: blake{at}bibra.co.uk
| |
Abbreviations |
|---|
Abbreviations used are:
P450, cytochrome P450;
BNF,
-naphthoflavone;
RIF, rifampicin;
DEX, dexamethasone;
LANS, lansoprazole;
MCP, methylclofenapate;
NaPB, sodium phenobarbital;
DMSO, dimethyl sulfoxide.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
U. Savas, D. E. W. Machemer, M.-H. Hsu, P. Gaynor, J. M. Lasker, R. H. Tukey, and E. F. Johnson Opposing Roles of Peroxisome Proliferator-activated Receptor {alpha} and Growth Hormone in the Regulation of CYP4A11 Expression in a Transgenic Mouse Model J. Biol. Chem., June 12, 2009; 284(24): 16541 - 16552. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ning, S. Dial, Y. Sun, J. Wang, J. Yang, and L. Guo Systematic and Simultaneous Gene Profiling of 84 Drug-Metabolizing Genes in Primary Human Hepatocytes J Biomol Screen, March 1, 2008; 13(3): 194 - 201. [Abstract] [PDF] |
||||
![]() |
P. Afsharian, Y. Terelius, Z. Hassan, C. Nilsson, S. Lundgren, and M. Hassan The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats Clin. Cancer Res., July 15, 2007; 13(14): 4218 - 4224. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Itoh, M. Nakajima, E. Higashi, R. Yoshida, K. Nagata, Y. Yamazoe, and T. Yokoi Induction of Human CYP2A6 Is Mediated by the Pregnane X Receptor with Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator 1{alpha} J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 693 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, et al. EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 1004 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Katoh, T. Matsui, M. Nakajima, C. Tateno, Y. Soeno, T. Horie, K. Iwasaki, K. Yoshizato, and T. Yokoi IN VIVO INDUCTION OF HUMAN CYTOCHROME P450 ENZYMES EXPRESSED IN CHIMERIC MICE WITH HUMANIZED LIVER Drug Metab. Dispos., June 1, 2005; 33(6): 754 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Donato, A. Serralta, N. Jimenez, G. Perez, J. V. Castell, J. Mir, and M. J. Gomez-Lechon LIVER GRAFTS PRESERVED IN CELSIOR SOLUTION AS SOURCE OF HEPATOCYTES FOR DRUG METABOLISM STUDIES: COMPARISON WITH SURGICAL LIVER BIOPSIES Drug Metab. Dispos., January 1, 2005; 33(1): 108 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Bjornsson, J. T. Callaghan, H. J. Einolf, V. Fischer, L. Gan, S. Grimm, J. Kao, S. P. King, G. Miwa, L. Ni, et al. THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE Drug Metab. Dispos., July 1, 2003; 31(7): 815 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Bjornsson, J. T. Callaghan, H. J. Einolf, V. Fischer, L. Gan, S. Grimm, J. Kao, S. P. King, G. Miwa, L. Ni, et al. The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective J. Clin. Pharmacol., May 1, 2003; 43(5): 443 - 469. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||